Insights from Brii Bio's Study on siRNA and Chronic HBV
Brii Biosciences Limited, a notable biotechnology company developing therapies for unmet medical needs, presented compelling results from its Phase 2 ENSURE study during a late-breaking session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024. This significant study highlighted the effectiveness of elebsiran (BRII-835, VIR-2218) when combined with pegylated interferon alpha (PEG-IFN?) in patients suffering from chronic hepatitis B virus (HBV) infection.
Effective Combination Therapy Results
The ENSURE trial aimed to assess the therapeutic impact of elebsiran in patients with chronic HBV, particularly emphasizing those with baseline hepatitis B surface antigen (HBsAg) levels between 100 to 3,000 IU/mL. The latest 48-week end-of-treatment (EOT) data illustrates a striking enhancement in the functional cure rate when combining elebsiran with PEG-IFN?. Among participants who received 200 mg of elebsiran, 26.3% achieved HBsAg seroclearance, while an impressive 33.3% of those receiving 100 mg reached the same endpoint. In contrast, only 5.6% of the group treated with PEG-IFN? alone exhibited similar results.
The Significance of These Findings
According to Dr. Jidong Jia, a leading physician at the Liver Research Centre in Beijing, these outcomes spotlight the potential of combining siRNA therapies with established ones like PEG-IFN?. He remarked on the transformational implications of these results, given the broader context of patients previously facing limited treatment options for chronic HBV.
Broader Implications for HBV Treatment
David Margolis, MD, the Chief Medical Officer of Brii Bio, expressed optimism regarding the potential of elebsiran. He stated, "Our findings support our ambition to establish a functional cure for chronic HBV among diverse populations. The data reinforces elebsiran as a key component of future combination therapies designed to enhance cure rates for the approximately 254 million individuals globally living with chronic HBV. We are committed to progressing through ongoing Phase 2 studies to validate these treatments further."
Key Data Points from the ENSURE Study
- In the sub-group with baseline HBsAg levels ranging from 100 - 1,500 IU/mL, the seroclearance rates demonstrated similarly promising results, with 31.3% and 40.0% of participants achieving seroclearance when receiving 200 mg and 100 mg of elebsiran, respectively.
- The study revealed significantly greater reductions in HBsAg levels in those receiving combination therapy, reinforcing the added value provided by elebsiran. Those treated with the higher dose of elebsiran exhibited an average reduction of -2.47 log10 IU/mL compared to -1.02 log10 IU/mL for PEG-IFN? alone.
- Overall, the combination therapy was well-tolerated among participants, emphasizing its potential as a safe alternative for those seeking treatment for chronic HBV.
- The long-term follow-up post-treatment is currently ongoing, intending to gather additional safety and efficacy data over the next 24 weeks.
Brii Bio's Innovative Approach to HBV
The findings from the ENSURE trial are a key part of Brii Bio's broader strategy to develop innovative treatments for HBV. The company continues to progress with a diversified portfolio that includes other promising compounds, such as tobevibart—a monoclonal antibody designed specifically to target HBV—and BRII-179, a recombinant protein-based immunotherapeutic. As the company advances its research, important findings and data compilations will be presented at scientific conferences in the upcoming months, establishing Brii Bio as a formidable player in the field of infectious diseases.
Understanding Hepatitis B
The hepatitis B virus is recognized globally as a serious public health concern, affecting over 254 million individuals worldwide. Chronic HBV is a leading cause of liver-related diseases, with significant mortality stemming from complications associated with the infection. It holds critical implications in regions heavily impacted by the virus, particularly where millions live with chronic hepatitis, emphasizing the urgency for effective treatment options.
About Brii Bio
Brii Biosciences Limited, known by stock code 2137.HK, is at the forefront of battling complex health issues, particularly in infectious diseases and central nervous system disorders. With a commitment to addressing public health challenges, Brii Bio continues developing a robust pipeline aimed at delivering innovative therapeutic solutions for patients facing challenging health conditions. The company operates across key biotech locations, including Raleigh-Durham, the San Francisco Bay Area, Beijing, and Shanghai
Frequently Asked Questions
What is the significance of the Phase 2 ENSURE study?
The ENSURE study is crucial as it evaluated the effectiveness of elebsiran combined with PEG-IFN?, showcasing higher HBsAg seroclearance rates compared to PEG-IFN? alone, indicating a potential pathway toward achieving functional cures for HBV.
How does elebsiran work?
Elebsiran is an investigational siRNA designed to degrade HBV RNA, thereby limiting the production of hepatitis B surface antigen, which is vital for managing chronic HBV infection.
What are the potential benefits of combining elebsiran with PEG-IFN??
The combination therapy aims to enhance virological responses and achieve higher cure rates, providing an alternative treatment strategy for chronic HBV patients.
How is the safety of elebsiran evaluated?
Throughout the ENSURE study, elebsiran demonstrated a favorable safety profile, with participants generally tolerating the treatment well.
What is Brii Bio's vision for HBV treatments?
Brii Bio aims to provide innovative and effective treatment solutions for chronic HBV, focusing on developing therapies that can significantly improve patient outcomes on a global scale.
